# XOMA (US) LLC clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with XOMA (US) LLC as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by XOMA (US) LLC: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/xoma-us-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 13, 2016 | NCT02772718 | An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery | XOMA (US) LLC | Phase 2 | Completed | Hypoglycemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02772718) |
| November 13, 2015 | NCT02604485 | A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism | XOMA (US) LLC | Phase 2 | Completed | Congenital Hyperinsulinism | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02604485) |
| December 29, 2014 | NCT02326740 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | XOMA (US) LLC | Phase 3 | Terminated | Pyoderma Gangrenosum | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02326740) |
| December 17, 2014 | NCT02318914 | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum | XOMA (US) LLC | Phase 3 | Terminated | Pyoderma Gangrenosum | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02318914) |
| December 11, 2014 | NCT02315417 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | XOMA (US) LLC | Phase 3 | Terminated | Pyoderma Gangrenosum | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02315417) |
| November 18, 2014 | NCT02293564 | Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand | XOMA (US) LLC | Not applicable | Completed | Osteoarthritis | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02293564) |
| October 8, 2014 | NCT02258867 | Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis | XOMA (US) LLC | Phase 3 | Terminated | Behcet's Disease Uveitis | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02258867) |
| October 8, 2014 | NCT02258854 | An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data | XOMA (US) LLC | Phase 3 | Terminated | Uveitis | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02258854) |
| September 25, 2013 | NCT01950312 | The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease | XOMA (US) LLC | Phase 2 | Completed | Autoimmune Inner Ear Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01950312) |
| June 20, 2013 | NCT01882504 | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum | XOMA (US) LLC | Phase 2 | Completed | Pyoderma Gangrenosum | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01882504) |
| June 20, 2013 | NCT01882491 | Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand | XOMA (US) LLC | Phase 2 | Completed | Osteoarthritis | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01882491) |
| December 11, 2012 | NCT01747538 | Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment | XOMA (US) LLC | Phase 3 | Terminated | Uveitis | 281 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01747538) |
| September 12, 2012 | NCT01684345 | Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis | XOMA (US) LLC | Phase 3 | Terminated | Uveitis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01684345) |
| September 11, 2012 | NCT01683396 | Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand | XOMA (US) LLC | Phase 2 | Completed | Osteoarthritis | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01683396) |
| December 26, 2011 | NCT01498874 | Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris | XOMA (US) LLC | Phase 2 | Completed | Acne Vulgaris | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01498874) |
| June 16, 2010 | NCT01144975 | Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus | XOMA (US) LLC | Phase 2 | Completed | Type 2 Diabetes Mellitus | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01144975) |
| February 10, 2010 | NCT01066715 | Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy | XOMA (US) LLC | Phase 2 | Completed | Type 2 Diabetes Mellitus | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01066715) |
| October 20, 2009 | NCT00998699 | Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes | XOMA (US) LLC | Phase 2 | Completed | Type 1 Diabetes | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00998699) |
| October 22, 2008 | NCT00777816 | Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis | XOMA (US) LLC | Phase 2 | Suspended | Rheumatoid Arthritis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00777816) |
| October 10, 2007 | NCT00541983 | Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus | XOMA (US) LLC | Phase 1 | Completed | Type 2 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00541983) |
| August 8, 2007 | NCT00513214 | Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus | XOMA (US) LLC | Phase 1/2 | Completed | Type 2 Diabetes | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00513214) |
| March 30, 2007 | NCT00454155 | Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | XOMA (US) LLC | Phase 1/2 | Terminated | Graft Versus Host Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00454155) |
| January 16, 2003 | NCT00051675 | Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas | XOMA (US) LLC | Phase 1 | Completed | Adenocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00051675) |
| January 16, 2003 | NCT00051662 | Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis | XOMA (US) LLC | Phase 1 | Completed | Psoriatic Arthritis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00051662) |
| April 25, 2002 | NCT00034203 | Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis. | XOMA (US) LLC | Phase 2 | Completed | Rheumatoid Arthritis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00034203) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 12 |
| Phase 3 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 8 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Uveitis | 4 |
| Pyoderma Gangrenosum | 4 |
| Uveitis, Intermediate | 3 |
| Uveitis, Posterior | 3 |
| Panuveitis | 3 |
| Osteoarthritis | 3 |
| Hypoglycemia | 2 |
| Arthritis, Rheumatoid | 2 |
| Graft vs Host Disease | 1 |
| Labyrinth Diseases | 1 |
| Meniere Disease | 1 |
| Hearing Loss, Sudden | 1 |
| Diabetes Mellitus, Type 1 | 1 |
| Behcet Syndrome | 1 |
| Arthritis, Psoriatic | 1 |
| Congenital Hyperinsulinism | 1 |
| Adenocarcinoma | 1 |
| Arthritis | 1 |
| Acne Vulgaris | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
- [Tex-Mex restaurants in the United States](https://specstream.ai/data/businesses/tex-mex-restaurants/united-states)
- [Music schools in the United States](https://specstream.ai/data/businesses/music-schools/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
